Mark Taylor - Concepedia

Author

Mark Taylor

Lancaster University ORCID

Also Known As

Mark Taylor

Publications

Citations

H-Index

Concepts

All Affiliations

Lancaster University Kyoto Prefectural University of Medicine Salford Royal Hospital University of Manchester University of Milano-Bicocca

About

Mark Taylor is an author at Lancaster University specializing in medicine, peptide science, and neurodegenerative diseases.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	396
2	Engineering	2	2	206
3	Natural Sciences	2	2	61
4	Allergy	1	1	10
5	Biochemistry	1	1	40

Mark Taylor

Publications

852

Citations

H-Index

Page 1

	Year	Citations
Phosphorylated α‐synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease Penelope G. Foulds, John Mitchell, Angela Parker, The FASEB Journal	2011	202
Development of a Proteolytically Stable Retro-Inverso Peptide Inhibitor of β-Amyloid Oligomerization as a Potential Novel Treatment for Alzheimer’s Disease Mark Taylor, Susan A. Moore, Jennifer Mayes, Biochemistry	2010	155
Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide Mark Taylor, Susan A. Moore, Spyridon Mourtas, Nanomedicine Nanotechnology Biology and Medicine NanoparticlesNanomedicineLipid Ligand-functionalized NanoliposomesAlzheimer's DiseaseNanotherapeutics	2011	145
Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration Penelope G. Foulds, Yvonne S. Davidson, Manjari Mishra, Acta Neuropathologica Frontotemporal Lobar DegenerationNeurodegenerative DiseasesCorticobasal DegenerationDegenerative DiseaseDegenerative Pathology	2009	93
A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease Vadivel Parthsarathy, Paula L. McClean, Christian Hölscher, PLoS ONE	2013	89
Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide Maria Gregori, Mark Taylor, Elisa Salvati, Nanomedicine Nanotechnology Biology and Medicine NanoparticlesNanomedicineNeurodegenerative DiseasesAlzheimer's DiseaseEngineering	2016	61
Designed Glycopeptidomimetics Disrupt Protein–Protein Interactions Mediating Amyloid β-Peptide Aggregation and Restore Neuroblastoma Cell Viability Julia Kaffy, Dimitri Brinet, Jean‐Louis Soulier, Journal of Medicinal Chemistry Peptide EngineeringGlycobiologyNeurochemical BiomarkersPeptide ScienceBiomedical Engineering	2016	40
Correlation of Aβ oligomer levels in matched cerebrospinal fluid and serum samples Takashi Kasai, Takahiko Tokuda, Mark Taylor, Neuroscience Letters Neuroimaging BiomarkersNeurodegenerative DiseasesAlzheimer's DiseaseCerebrospinal FluidAβ Oligomer Levels	2013	26
Mcm10 interacts with Rad4/Cut5TopBP1 and its association with origins of DNA replication is dependent on Rad4/Cut5TopBP1 Mark Taylor, Karen Moore, Johanne M. Murray, DNA repair ChromatinGenome InstabilityNatural SciencesGeneticsDna Replication	2011	21
Utilization of a multiple antigenic peptide as a calibration standard in the BAN50 single antibody sandwich ELISA for Aβ oligomers Takashi Kasai, Takahiko Tokuda, Mark Taylor, Biochemical and Biophysical Research Communications AllergyCalibration StandardBioanalysisImmunologyMultiple Antigenic Peptide	2012	10

Page 1